Shearman & Sterling advised Credit Suisse, BofA Securities, SVB Securities and Van Lanschot Kempen acting as private placement agents in the business combination and $91 million PIPE transaction between European Biotech Acquisition Corp. and Oculis SA.
The transaction was announced on Nov. 7, 2022 and closed on March 3, 2023. The shares and warrants began trading on the Nasdaq under the ticker symbols “OCS” and “OCSAW”, respectively, on March 3. At closing, Oculis had a pro-forma enterprise value of approximately $220 million and a cash balance exceeding $109 million.
Credit Suisse, BofA Securities, SVB Securities, Van Lanschot Kempen and Arctica Finance acted as joint private placement agents for the business combination.
Oculis is a clinical-stage biopharmaceutical company, based in Switzerland, with substantial expertise in therapeutics used to treat ocular diseases. European Biotech Acquisition Corp. is a special purpose acquisition company sponsored by an affiliate of Life Sciences Partners.